(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 July 2010 (29.07.2010)

PCT

(10) International Publication Number
WO 2010/083582 A1

(51) International Patent Classification:
A61K 31/4412 (2006.01) *A61P 27/02* (2006.01)

(21) International Application Number:
PCT/CA2009/001639

(22) International Filing Date:
12 November 2009 (12.11.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/147,245 26 January 2009 (26.01.2009) US

(72) Inventors; and
(71) Applicants : **SPINO, Michael** [CA/CA]; 948 Duncannon Drive, Pickering, Ontario L1X 2P3 (CA). **DUNAIEF, Joshua Lawrence** [US/US]; 305 Stellar Chance Laboratories, 422 Curie Blvd., Philadelphia, Pennsylvania 19104 (US).

(74) Agent: **MCKINNON, Graham, JK**; Apotex Inc., 150 Signet Drive, Toronto, Ontario M9L 1T9 (CA).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*


— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: USE OF DEFERIPRONE FOR TREATMENT AND PREVENTION OF IRON-RELATED EYE DISORDERS

Fig. 7



(57) Abstract: There is provided use of orally available or topically applied deferiprone for prevention of iron-induced eye damage. The use may be for preparation of a medicament or in a method of preventing iron-induced eye damage to an eye of a subject at risk for iron-induced eye damage, the method comprising administering a prophylactically effective amount of deferiprone to the subject. There is also provided the use of deferiprone for treatment of iron-related eye disorders. The use may be for preparation of a medicament or in a method of treatment of damage to an eye of a having eye damage associated with iron, the method comprising topically administering a therapeutically effective amount of deferiprone to the subject.

WO 2010/083582 A1